Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial

Abstract excerpt

<h4>Summary</h4> <h4>Background</h4> SARS-CoV-2 is a novel human coronavirus, there is no specific antiviral drugs. It has been proved that host-cell-expressed CD147 could bind spike protein of SARS-CoV-2 and involve in host cell invasion. Antibody against CD147 could block the infection of SARS-CoV-2. We aimed to assess the efficacy and safety of meplazumab, a humanized anti-CD147 antibody, as add-on therapy in p...

Topics

Open a Topic to create a Post that cites this publication.

• Biosensing Techniques
• COVID-19 Drug Treatment
• COVID-19 Vaccines
• Dexamethasone
• Glucocorticoids
• Molecular Diagnostic Techniques
• Nucleic Acid Amplification Techniques
• World Health Organization

Identifiers and source

Literature Corpus work

26aaea14-a1c4-58f4-954e-7f6bc0cffd64

DOI

10.1101/2020.03.21.20040691